



## Clinical discussion points

---

- What do you think of the methods of the review?
  - How confident are you in the results and conclusions? Can you use them in making decisions about treatment of your patients?
  - Are the included patients similar enough to your patients? If not, how do they differ and what are the implications?
  - Over what timeframe have the biologic DMARDs been tested in the included studies? Is that long enough to help you make a decision?
- Based on the overview's results, would you consider using biologic DMARDs for your patients?
  - Is ACR50 a good measure for comparing the drugs?
  - Is withdrawal a good enough guide to adverse effects?
  - What other information would you need to assess harms?
  - What other results from this overview or from the individual Cochrane reviews would help inform your decision?
  - The review also collated information on radiological changes. What might be the significance of this outcome measure, and why should we be cautious in interpreting the findings at present?
  - What other drugs would you consider using if biologic DMARDs are not suitable or available?
- What other information would you want to use in making a decision about using biologic DMARDs?
  - What's your personal, and clinic, experience of using the drugs?
  - What preferences would your patients have for the various potential benefits and harms, and the different ways of receiving the drugs?